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No association of a 306-bp insertion polymorphism
in the progesterone receptor gene with ovarian and
breast cancer
Sir
Chromosome region 1lq22-23 is a site of frequent loss of
heterozygosity (LOH) in breast cancer (Hampton et al, 1994a),
ovarian cancer (Davis et al, 1996) and other malignancies
(Keldysh et al, 1993; Hampton et al, 1994b; Herbst et al, 1995),
suggesting the presence of an important tumour-suppressor
gene(s) (TSG). The most obvious candidate in the region, the gene
responsible for ataxia telangiectasia, has recently been ruled out as
the target of these deletions in breast cancer (Vorechovsky et al,
1996). The human progesterone receptor (PR) gene is also located
in this region (Rousseau-Merck et al, 1987), and there is evidence
that it may have tumour-suppressing properties. For example, in
ovarian cancer, LOH atthe PR locus is associated with reduced PR
protein levels (Gabra et al, 1995a) and with adverse clinicopatho-
logical features (Gabra et al, 1995b). Furthermore, there is an asso-
ciation between PR levels and histological subtypes of ovarian
cancer (Vierikko et al, 1983). In particular, endometrioid tumours
contain elevated PR levels relative to other histological subtypes
(Slotman et al, 1990). In breast cancer, similar relationships
between PR expression and tumour behaviour (Stierer et al, 1993)
and PR expression and llq LOH (Magdelenat et al, 1994) have
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Figure 1 Representative agarose gel displaying PCR products of 139 bp
(Ti) and 445 bp (T2). Homozygotes lacking the 306-bp PROGINS insertion
(lanes 1, 2, 3, 5, 6, 7, 8), heterozygotes for the PROGINS insertion (lanes 9
and 10) and a homozygote for the PROGINS insertion (lane 4) are shown
been documented. These observations are consistent with a
tumour-suppressive role for PR and suggest that it is the target of
the Ilq22-23 LOH.
In the context of these studies, common polymorphisms of the
PR gene that may encode aberrant forms of the PR have been
investigated for their association with breast and ovarian cancers.
One such polymorphism, designated PROGINS, consists of a 306-
bp insertion of the PV/HS-l Alu subfamily in intron G of the PR
gene (Rowe et al, 1995). Rowe et al speculated that this insertion
might result in expression of an aberrant splice form of PR with
altered ligand and hormone-binding properties, since itintroduces a
consensus splice acceptor site just downstream of a consensus
splice donor site. An increased frequency of the PROGINS allele
(T2) has been reported in patients with ovarian cancer (McKenna et
al, 1995) and breast cancer (Garrett etal, 1995). However, the asso-
ciation with ovarian cancer was based on a total of only 67 cases,
26 from Germany and 41 from Ireland (McKenna et al, 1995). In
the breast cancer study, the frequency of the PROGINS allele
among 187 cases was increased compared with the 90 controls but
did not reach statistical significance (Garrett et al, 1995).
We assessed the frequency of the PROGINS allele in the
genomic DNA from 231 sporadic ovarian cancer cases, 292 breast
cancer cases and a control group of 220 healthy volunteers in a
region of southern England. Previous Polymerase chain reaction
(PCR) analyses of the distribution of the TI and T2 allele used
primers that flank regions of3.0 kb (T2) and 2.7 kb (TI) (Rowe et
al, 1995), which were inherently difficult to amplify and resolve
on agarose gels. We developed a new set of primers that produce
products of455 bp (T2) and 149 bp (TI), which were amenable to
amplification and easily resolved on 1.5% mini agarose gels, as
shown in Figure 1. The distribution ofthe TI and T2 alleles in the
breast cancer, ovarian cancer and non-cancer control groups are
shown in Table 1. No significant differences could be demon-
strated in the distribution ofthe alleles between the control group
Table 1 Distribution and frequencies of the PR gene alleles in ovarian cancer, breast cancer and control groups
Genotype
Ti/Ti T1/T2 T2/T2
Group Total n' frequencyb n frequency n frequency T2 frequencyd
(95% cl) (95% Cl) (95% Cl) (95% Cl)
Ovarian 231 173 74.9 (69-80) 52 22.5 (17-28) 6 2.6 (1-6) 0.11 (0.09-0.14)
cancer
Breast 292 229 78.4 (74-83) 61 20.9 (16-26) 2 0.7 (0-2) 0.14 (0.11-0.17)
cancer
Control group 220 162 73.6 (68-79) 54 24.5 (19-30) 4 1.8 (0-5) 0.14 (0.11-0.17)
aNumber of individuals with genotype. bFrequency expressed as a percentage of the total. cNumbers in parentheses are 95% confidence intervals. dObserved
allele frequency. Genotypic distributions of breast and ovarian cancer did not differ significantly from control groups (breast cancer, P= 0.73; ovarian cancer,
P= 0.86).
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and the ovarian (P = 0.86) or breast cancer (P = 0.73) groups. The
observed frequency distribution of the alleles TI and T2 were
compared with the expected allele frequency distribution
according to the Hardy-Weinberg equation, and X2 analysis
revealed no significant differences, with the ovarian cancer, breast
cancer and control groups all following the expected distributions.
The frequency of the T1/T2 heterozygotes in our control group
(24.5%) was similar to that observed in previous studies ofan Irish
population (25.5%) but was significantly higher than that found in
a German population (12%) (McKenna et al, 1995). Our finding
that there is no significant difference between the frequency of the
PROGINS allele in patients with ovarian cancer and the non-
cancer control group is at variance with the findings of McKenna
et al. They based the association with ovarian cancer on a study of
41 cancer patients and 83 control subjects from Ireland and 26
cancer patients and 101 control subjects from Germany (McKenna
et al, 1995). An over-representation ofthe Tl/T2 heterozygote was
demonstrated among the pooled Irish and German cancer groups
(35%) compared with the pooled controls groups (18%). However,
when analysed separately neither the Irish nor German cancer
groups could be demonstrated to differ significantly from the
corresponding control groups. In fact, the only reason the pooled
results reached statistical significance was that the frequency of
the T2 allele in the German control group was very low (0.07
compared with the Irish control group frequency of0.17).
To investigate further the potential cancer predisposing influ-
ence of the PROGINS allele, we analysed for LOH in the ovarian
cancer cases by assessing the PCR products obtained from periph-
eral blood leucocyte DNA and tumour DNA for allelotype loss.
We reasoned that, if PROGINS represents a defective copy of the
PR gene, then according to the two-hit hypothesis of Knudson
(1971), LOH at this locus should remove the wild-type allele.
Matching tumour DNA was available for 11 of the 52 ovarian
tumours that were heterozygous for the PROGINS allele. LOH
was detected in four ofthe 11 cases and in each instance it was the
PROGINS allele that was deleted. This finding is consistent with
the absence of an association ofPROGINS with the cancer groups
and supports our view that PROGINS has no functional signifi-
cance with respect to cancer predisposition.
Despite this lack of association, the PR gene remains a good
candidate for the target ofthe 1lq22-23 LOH. Our finding of36%
LOH at this locus in ovarian cancer together with the work of
Gabra et al (1995a, b) supports the theory that genetic alterations
in the PR gene may be important in the development of ovarian
cancer and other malignancies.
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